Literature DB >> 15367397

Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone.

May-yun Wang1, Roger H Unger.   

Abstract

In obese rodents, excess myocardial lipid accumulation (lipotoxicity) of myocardium may cause cardiomyopathy that in the obese Zucker diabetic fatty (ZDF) fa/fa rat can be prevented by treatment with troglitazone (TGZ). To determine the underlying mechanisms, we measured total 5'-AMP-activated kinase (AMPK) protein and its activated, phosphorylated form, P-AMPK. P-AMPK was significantly reduced in both ZDF fa/fa rat and ob/ob mouse hearts compared with lean, wild-type controls. TGZ treatment of obese ZDF rats, which lowered cardiac lipid content, increased P-AMPK. Expression of protein phosphatase 2C (PP2C), which inactivates AMPK activity by dephosphorylation, was increased in untreated ZDF fa/fa rat hearts, but fell with TGZ treatment, suggesting that PP2C can influence AMPK activity. In cultured myocardiocytes, fatty acids reduced P-AMPK, suggesting a feed-forward effect of lipid overload. Our findings highlight a role of PP2C and AMPK in the derangements of cardiac lipid metabolism in obesity and provide new insights as to the mechanisms of the liporegulatory disorder leading to lipotoxic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367397     DOI: 10.1152/ajpendo.00004.2004

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  38 in total

1.  Activation of AMP-activated protein kinase stimulates Na+,K+-ATPase activity in skeletal muscle cells.

Authors:  Boubacar Benziane; Marie Björnholm; Sergej Pirkmajer; Reginald L Austin; Olga Kotova; Benoit Viollet; Juleen R Zierath; Alexander V Chibalin
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

Review 2.  Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Authors:  Tian Li; Shuai Jiang; Zhi Yang; Zhiqiang Ma; Wei Yi; Dongjin Wang; Yang Yang
Journal:  Cell Mol Life Sci       Date:  2016-11-04       Impact factor: 9.261

Review 3.  AMP-activated protein kinase regulation and biological actions in the heart.

Authors:  Vlad G Zaha; Lawrence H Young
Journal:  Circ Res       Date:  2012-08-31       Impact factor: 17.367

Review 4.  Fatty heart, cardiac damage, and inflammation.

Authors:  Maria A Guzzardi; Patricia Iozzo
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 5.  AMPK inhibition in health and disease.

Authors:  Benoit Viollet; Sandrine Horman; Jocelyne Leclerc; Louise Lantier; Marc Foretz; Marc Billaud; Shailendra Giri; Fabrizio Andreelli
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-08       Impact factor: 8.250

6.  Intramyocellular lipids: maker vs. marker of insulin resistance.

Authors:  Zengkui Guo
Journal:  Med Hypotheses       Date:  2007-09-04       Impact factor: 1.538

7.  Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts.

Authors:  Imene Tabbi-Anneni; Jonathan Buchanan; Robert C Cooksey; E Dale Abel
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

8.  Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice.

Authors:  Ni-Huiping Son; Tae-Sik Park; Haruyo Yamashita; Masayoshi Yokoyama; Lesley A Huggins; Kazue Okajima; Shunichi Homma; Matthias J Szabolcs; Li-Shin Huang; Ira J Goldberg
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 9.  Abdominal obesity and the metabolic syndrome: a surgeon's perspective.

Authors:  Patrick Mathieu
Journal:  Can J Cardiol       Date:  2008-09       Impact factor: 5.223

10.  Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography.

Authors:  Charissa E van den Brom; Marc C Huisman; Ronald Vlasblom; Nicky M Boontje; Suzanne Duijst; Mark Lubberink; Carla F M Molthoff; Adriaan A Lammertsma; Jolanda van der Velden; Christa Boer; D Margriet Ouwens; Michaela Diamant
Journal:  Cardiovasc Diabetol       Date:  2009-07-22       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.